Share this video  

ESMO 2021 | KEYNOTE-716: pembrolizumab for patients with high-risk stage II melanoma

Ines Pires da Silva, MD, PhD, Melanoma Institute Australia and The University of Sydney, Sydney, Australia, comments on the results of the Phase III KEYNOTE-716 trial (NCT03553836) evaluating the safety and efficacy of pembrolizumab in patients with high-risk stage II melanoma. Whilst this study showed significantly improved outcomes for this patient population, additional data and a longer follow-up period are required to validate those results. In addition, despite its proven benefits, the approval of this treatment might take a significant amount of time. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.


Dr da Silva reports travel support by BMS and MSD, and speaker fee by Roche, BMS, MSD and Novartis.